Please login to the form below

Not currently logged in
Email:
Password:

Ogeda

This page shows the latest Ogeda news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

have acquired Ogeda and its phase IIa candidate Fezolinetant.

Latest news

  • Astellas agrees €800m deal to buy Belgian biotech Ogeda Astellas agrees €800m deal to buy Belgian biotech Ogeda

    Astellas agrees 800m deal to buy Belgian biotech Ogeda. Will pay another 300m if fezolinetant meets clinical and regulatory targets. ... The parties expect the deal to close this quarter, after which Ogeda will become a wholly-owned subsidiary of Astellas

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    An example of a big pharma buying a company with a new technology/ product is Astellas which acquired the venture capital owned Belgian company Ogeda for up to $872m. ... Ogeda is developing drugs targeting G-protein coupled receptors. The lead product

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics